- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01198834
MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains
January 14, 2018 updated by: MEDRx USA, Inc.
A Randomized, Multi-Center, Double-Blind, Factorial, Comparator and Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains
A Randomized, Multi-Center, Double-Blind, Factorial, Comparator and Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
600
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85050
-
-
Arkansas
-
North Little Rock, Arkansas, United States, 72114
-
-
California
-
Chico, California, United States, 95929
-
Palm Springs, California, United States, 92262
-
San Diego, California, United States, 92120
-
-
Colorado
-
Aurora, Colorado, United States, 80014
-
Colorado Springs, Colorado, United States, 80907
-
Denver, Colorado, United States, 80239
-
-
Florida
-
Daytona Beach, Florida, United States, 32114
-
Fort Lauderdale, Florida, United States, 33334
-
Gulf Breeze, Florida, United States, 32561
-
Orlando, Florida, United States, 32804
-
West Palm Beach, Florida, United States, 33409
-
-
Idaho
-
Boise, Idaho, United States, 83702
-
-
Indiana
-
Avon, Indiana, United States, 46123
-
Fishers, Indiana, United States, 46038
-
Franklin, Indiana, United States, 46131
-
Greenfield, Indiana, United States, 46140
-
Muncie, Indiana, United States, 47304
-
-
Iowa
-
Dubuque, Iowa, United States, 52001
-
-
Kansas
-
Wichita, Kansas, United States, 67206
-
-
Kentucky
-
Erlanger, Kentucky, United States, 41018
-
-
Nevada
-
Henderson, Nevada, United States, 89502
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
-
-
North Dakota
-
Fargo, North Dakota, United States, 58103
-
-
Ohio
-
Cincinnati, Ohio, United States, 45246
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
-
-
Texas
-
Georgetown, Texas, United States, 78626
-
Lubbock, Texas, United States, 79410
-
San Antonio, Texas, United States, 78229
-
Temple, Texas, United States, 76502
-
-
Utah
-
Riverton, Utah, United States, 84065
-
-
Virginia
-
Danville, Virginia, United States, 24541
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
A subject will be eligible for inclusion in this study if all of the following criteria apply:
- Subject has signed an informed consent form.
- Subject is 14 years of age or older (with assent according to state law).
- Females of child bearing potential must have a negative pregnancy test and be using an adequate method of birth control. Adequate is defined as either hormonal or partner vasectomy for at least three months, or , condoms, IUD, abstinence or other prescribed birth control. Females may be considered non-childbearing if post-menopausal at least 1 year or surgically sterile.
- Subject has a diagnosis of uncomplicated acute soft tissue inversion injury of the ankle, Grade II classification (as defined by the American Academy of Orthopaedic Surgeons (AAOS), "partial tearing of the ligament") that has occurred ≥ 6 hours to ≤ 48 hours before study entry.
- Subject has a Current Pain Intensity during point and flex with the ankle unwrapped rated prior to study entry as ≥ 5 but ≤ 8 on an NPRS (11 point; range 0 to 10; anchors to be "none" and "severe").
- Subject is willing and able to comply with the protocol.
Exclusion Criteria
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Females of child bearing potential that are not using an adequate method of birth control or are breastfeeding (adequate defined as either hormonal or partner vasectomy for at least three months, or other prescribed birth control, condoms, IUD, abstinence or other prescribed birth control).
- Subject has a Grade I ("slight stretching and some damage to the fibers (fibrils) of the ligament") or Grade III ("complete tear of the ligament") sprain or strain, bilateral sprain or strain, or concomitant fracture or open wound at the site of the sprain or strain, or has a serious injury, as determined by the investigator (e.g., nerve damage, joint instability, or tendon rupture); or surgical treatment is required. Diagnosis of Grade III is indicated by a positive anterior drawer test or positive talar tilt test is exclusionary (inability to perform test(s) is exclusionary when in the opinion of the investigator a Grade III sprain is suspected).
- Subject has a history of a previous injury to the same area within two months prior to current injury or previous surgery in the same area.
- Subject has used non-pharmacologic treatments for the injury within 2 hours prior to the baseline visit (e.g. ice or acupuncture) that may interfere with pain assessments. Subjects on any therapeutic exercise regimen should continue based on the investigator's discretion. Use of iontophoresis is prohibited.
- Subject has used oral pharmacologic treatments (NSAIDs or analgesic medications) for the injury less than three half-lives before the baseline assessments; ibuprofen is permitted prior to baseline as long as it is not within six hours of the baseline assessment aspirin (81-325 mg daily) taken prophylactically for cardiovascular reasons is permitted.
- Subject has used any form of opioid within 24 hours of study entry or used opioids for five or more consecutive days within the 30 days preceding the screening visit.
- Subject has received systemic corticosteroids in the 30 days preceding the screening visit (e.g., intra-articular, peritendinous, oral, or parenteral administration); topical corticosteroid use is acceptable unless applied to the target joint; and inhaled steroids are acceptable (e.g. Flonase®).
- Subject recently initiated sleep medications, muscle relaxants, anticonvulsants or antidepressants (within the past 30 days); if using any of these, subject must be on a stable dose and regimen for 30 days prior to study enrollment.
- Subject has used TNF alpha blockers or Class 1 anti-arrhythmic drugs within the 60 days preceding the screening visit.
- Subject has a history or physical assessment finding of clinically significant GI ulcers or abnormal bleeding, anemia, kidney disease, liver disease, poorly controlled lung, stomach, heart, or other vital organ disease as determined by the study investigator/physician.
- Subject has a history or physical assessment finding that is not compatible with safe participation in the study as determined by the study investigator.
- Subject has any form of inflammatory arthritis, spondyloarthropathies (sPA), fibromyalgia, or is currently undergoing treatment for chronic pain; or has a history of, or evidence for, underlying disease in the injured area, such as osteoarthritis or gout.
- Subject has any pain or medical problem that, in the investigator's opinion, may interfere with pain measurement of the target joint.
- Subject has active skin lesions or disease at the intended site of application of the study medication. Skin lesions include open wounds, rash, papules and vesicles; abrasions, lacerations or any break in skin at the intended site of patch application.
- Subject has a history of allergy to etodolac, other NSAIDs, lidocaine, or adhesives (e.g. adhesive tape).
- Subject has a history of prior failed treatment with topical NSAIDs (Flector® Patch or Voltaren® Gel) defined as repeated attempts within the three months preceding the screening visit.
- Subject has a history of drug or alcohol abuse within the past two years preceding the screening visit.
- Subject has received an investigational drug or product or participated in an investigational drug study within a period of 30 days prior to receiving study medication.
- Subject has scheduled elective surgery or other invasive procedures during the period of study participation.
- Subject is on workman's compensation or has pending legal hearings associated with any injury.
- Subject refuses to provide informed consent or is unwilling or unable to follow study procedures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Patch
Treatment with Placebo Patch
|
Application of up to two patches at the discretion of the investigator for up to 7 days.
|
Experimental: MRX-7EAT Patch
Treatment with MRX-7EAT Patch
|
Application of up to two patches at the discretion of the investigator for up to 7 days.
|
Experimental: Lidocaine Patch
Treatment with Lidocaine Patch
|
Application of up to two patches at the discretion of the investigator for up to 7 days.
|
Experimental: Etodolac Patch
Treatment with Etodolac Patch
|
Application of up to two patches at the discretion of the investigator for up to 7 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean of All Current Pain Intensity During Point and Flex Scores on Days 2 Through 7 on a 0-10 Numeric Pain Rating Scale (NPRS).
Time Frame: Days 2 to 7
|
Days 2 to 7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Current Pain Intensity during Point and Flex
Time Frame: Days 1 through 7
|
Days 1 through 7
|
Current Pain Intensity at Rest, Passive Stretch and Pain Intensity While Standing On a Single Foot
Time Frame: Each Clinical Visit
|
Each Clinical Visit
|
Impact on Physical Function
Time Frame: Days 1 to 7
|
Days 1 to 7
|
Total Number of Patches Used
Time Frame: Days 1 to 7
|
Days 1 to 7
|
Time to Pain Resolution
Time Frame: Days 1 to 7
|
Days 1 to 7
|
Assessment of Patch Adherence
Time Frame: Clinical Visit 2
|
Clinical Visit 2
|
Subject's Treatment Satisfaction
Time Frame: Clinical Visit 3
|
Clinical Visit 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Martine Francis, IL Pharma
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
September 9, 2010
First Submitted That Met QC Criteria
September 9, 2010
First Posted (Estimate)
September 10, 2010
Study Record Updates
Last Update Posted (Actual)
January 17, 2018
Last Update Submitted That Met QC Criteria
January 14, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Wounds and Injuries
- Leg Injuries
- Sprains and Strains
- Ankle Injuries
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anesthetics
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Cyclooxygenase 2 Inhibitors
- Lidocaine
- Etodolac
Other Study ID Numbers
- MRX-7EAT-1005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ankle Sprains
-
Riphah International UniversityRecruiting
-
Riphah International UniversityRecruitingAnkle SprainsPakistan
-
Taipei Medical University WanFang HospitalUnknown
-
Lazaros LazarouCompletedAnkle SprainsGreece
-
Centre Hospitalier Universitaire de Saint EtienneRecruiting
-
Sylvia Maher Mohsen Farid HannaNot yet recruiting
-
Lawson Health Research InstituteTerminated
-
Istanbul Bilgi UniversityCompleted
-
Universiteit AntwerpenUniversity Hospital, Antwerp; University of Ulster; Bern University of Applied...Recruiting
-
Christian OlsenUniversity of Copenhagen; University Hospital Bispebjerg and Frederiksberg; Regionshospitalet... and other collaboratorsUnknown
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States